Growth Factor News and Research

RSS

Explanation on resistance to taxane class of drugs

Scientists have uncovered critical new details about the mechanisms that modulate the response of ovarian cancer cells to chemotherapy.

10 Dec 2007

Depression nearly triples the risk of death following a heart attack

...even when accounting for other heart attack risk factors, according to research presented at the American College of Neuropsychopharmacology (ACNP) annual meeting, which showed that among 360 depressed, post myocardial infarction patients followed for more than six years, those who did not recover from their depression in the first six months were more than twice as likely to die.

10 Dec 2007

Lymphatic vessel and lymph node function are restored with growth factor treatment

The frequent spread of certain cancers to lymph nodes often necessitates surgery or radiation therapy that damages the lymphatic system and can cause lymphedema, a condition of localized fluid retention that often increases susceptibility to infections.

4 Dec 2007

Hydrogen sulfide provides clues to a longer life

Hydrogen sulfide, or H2S, the chemical that gives rotten eggs their sulfurous stench - and the same compound that researchers at Fred Hutchinson Cancer Research Center successfully have used to put mice into a state of reversible metabolic hibernation - has now been shown to significantly increase life span and heat tolerance in the nematode worm, or C. elegans.

4 Dec 2007

Eltrombopag studied in Idiopathic Thrombocytopenic Purpura

There are estimated to be between 50,000 -- 100,000 individuals in the U.S. diagnosed with chronic Immune Thrombocytopenic Purpura (ITP), an autoimmune disease that dramatically reduces the number of platelets in their blood -- causing bruises, nosebleeds and, sometimes, life-threatening brain hemorrhages.

29 Nov 2007

Discovery of key acute myeloid leukemia gene

A gene called N-Myc leads a double life in certain white blood cells, helping to trigger a cancer called acute myeloid leukemia (AML) under some conditions while triggering apoptosis, or cell suicide, under other conditions, according to results of a mouse study done by investigators at St. Jude Children's Research Hospital.

27 Nov 2007

Wyeth receives European approval for TORISEL

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the European Commission has approved TORISEL (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.

27 Nov 2007

How can we know early who will benefit from tumor target therapy?

The precise tailoring of tumor target treatment for patients with cancer is an unmet challenge.

21 Nov 2007

Hormone norepinephrine may hasten the progression of certain blood cancers

Researchers here have shown that in cell cultures, the stress hormone norepinephrine appears to promote the biochemical signals that stimulate certain tumor cells to grow and spread.

20 Nov 2007

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007

Diet low in carbohydrates may stunt prostate tumor growth

A diet low in carbohydrates may help stunt the growth of prostate tumors, according to a new study led by Duke Prostate Center researchers. The study, in mice, suggests that a reduction in insulin production possibly caused by fewer carbohydrates may stall tumor growth.

14 Nov 2007

Antibody might help starve cancerous tumors

An antibody might offer a safe and effective complement to anti-cancer therapies designed to starve malignant tumors by pruning the blood vessels that feed them, researchers report in the November 2 issue of the journal Cell, a publication of Cell Press.

2 Nov 2007

Breastfed babies breathe better, except when mother is asthmatic

When it comes to feeding babies, the old adage "breast is best" certainly holds true, with breastfed babies having less diarrhea and fewer ear infections and incidents of wheezing in early life.

2 Nov 2007

The role of growth factor in vertebrae formation

The Stowers Institute's Pourquié Lab has demonstrated the role of fibroblast growth factor (FGF) in the embryonic process of somitogenesis, an event required for vertebrae formation, in a paper posted to the Web site of the journal Development.

31 Oct 2007

How tumors respond to EGFR inhibitors

Three papers published this month in the open access general medical journal PLoS Medicine investigate how tumors respond to a an important class of drugs used in cancer chemotherapy, known as epidermal growth factor receptor (EGFR) inhibitors.

31 Oct 2007

Preventing lung scarring may extend lives of lung cancer patients

Researchers have found that using a special type of drug called a pharmaceutical monoclonal antibody to block the integrin beta6-TGF-beta pathway prevents a serious side effect of radiation therapy for lung cancer patients – pulmonary fibrosis (scarring of the lungs), thereby extending patients' lives and improving their quality of life, according to a study presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

29 Oct 2007

Blood markers can help choose best dose for antiangiogenic drugs

Scientists at Sunnybrook have new information that may help to improve the use of anti-cancer drugs designed to block the growth of new blood vessels in tumors, a process called angiogenesis that is critical to tumor growth.

25 Oct 2007

Low-density lipoprotein may contribute to vascular diseases

Low-density lipoprotein (LDL), a transporter of cholesterol, may also contribute to vascular diseases by a previously unidentified mechanism, according to a report published online this week in EMBO reports.

25 Oct 2007

Combination targets offer new hope in fight against cancer

While some targeted therapies - drugs developed to attack specific molecules in the critical chemical pathways occurring within cancer cells - work well by themselves, increasingly researchers are finding that they work better when teamed with other targeted and conventional therapies.

24 Oct 2007

Transparent zebrafish help the study inflammatory breast cancer

What if doctors could peer through a patient's skin and see a cancer tumor growing? They'd be able to study how tumor cells migrate: how they look, how they interact with the blood system to find nourishment to grow and spread through the body.

22 Oct 2007